(PHILADELPHIA) – Researchers at the University of Pennsylvania School of Medicine have identified a new strategy that Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) uses to dupe infected cells into replicating its viral genome. This allows the virus to remain virtually undetected by the body’s immune system. Previous work suggested KSHV needed viral proteins to initiate replication, but this is the first study to directly show that a section of viral DNA can independently draw upon proteins within a host cell to promote its own replication. The study was published in the August issue of Cell Host and Microbe.

“Without the necessary production of a viral protein, the virus goes unidentified by the immune system while utilizing the host cell’s replication machinery,” explains lead author Erle Robertson, PhD, Professor of Microbiology and Program Leader of Tumor Virology Program at Penn’s Abramson Cancer Center. Specifically, KSHV can overwhelm a weakened immune system, resulting in the development of Kaposi’s sarcoma and other diseases of the lymphocytes. 

A virus, comprised of only its genetic code wrapped in a protective protein cover, will infect a cell by penetrating its membrane and releasing the viral genome into the cell. Because viruses are asexual, they are dependent upon the replication proteins, or “machinery” of host cells to make new copies of their DNA material. To access the cellular proteins needed to replicate, Robertson says most scientists believed viruses must produce a viral protein.

“Our findings now break the long standing dogma of the virology field, which held that tumor viruses associated with human cancers do require a viral protein to bind and initiate replication,” notes Robertson. 

In the Robertson lab, previous studies of human cells infected with KSHV led researchers to locate a gene that codes for a viral protein called latency-associated nuclear antigen (LANA) that binds to viral DNA, signaling initiation of replication. To test whether or not KSHV replication was solely dependent upon LANA, the researchers eliminated the production of LANA by KSHV and introduced the LANA-free expression system into host cells. With viral protein production eliminated, the researchers discovered that KSHV DNA was capable of recruiting the cellular replication machinery proteins and so autonomously replicate.

“Once again, a virus has broken the mold in terms of our understanding of cellular processes and is teaching us new tricks about their ability to utilize the cellular mechanism for replication,” says Robertson. “By studying how viruses usurp this cellular function to their advantage, we can learn new bits of information about the mechanism of cellular replication in humans.”

In the future, Robertson and others plan to explore whether or not other viruses are capable of replicating without utilizing the role of viral proteins and learning more about cellular events that trigger replication. Also, researchers will look to identify ways to block KSHV from replicating without blocking cellular replication in order to stop the virus before it has a chance to overwhelm the immune system and progress into a disease.

Subhash C. Verma, Ke Lan, Tathagata Choudhuri, and Murray A. Cotter, all from Penn, were co-authors to this study.

This research was funded by the National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, The Leukemia and Lymphoma Society, and Lady Tata Memorial Trust for Research in Leukemia.

###

The Abramson Cancer Center (ACC) of the University of Pennsylvania is a national leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute for 30 years, one of 39 such Centers in the United States. The ACC is dedicated to innovative and compassionate cancer care. The clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient support specialists, currently sees over 50,000 outpatient visits, 3400 inpatient admissions, and provides over 25,000 chemotherapy treatments, and more than 65,000 radiation treatments annually. Not only is the ACC dedicated to providing state-of-the-art cancer care, the latest forms of cancer prevention, diagnosis, and treatment are available to our patients through clinical themes that developed in the relentless pursuit to eliminate the pain and suffering from cancer. In addition, the ACC is home to the 300 research scientists who work relentlessly to determine the pathogenesis of cancer. Together, the faculty is committed to improving the prevention, diagnosis and treatment of cancer.

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #3 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.